Search / Trial NCT00001759

Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Dec 9, 2002

Trial Information

Current as of December 27, 2024

Completed

Keywords

Allergy Fluorodeoxyglucose Imaging Pet Wegener's Granulomatosis Asthma

ClinConnect Summary

Asthma is a chronic inflammatory disease. We propose to study inflammatory changes in the lungs of subjects with atopic asthma of different severity in vivo using positron emission tomography (PET) with 2-deoxy-2-\[18F\]fluoro-D-glucose (FDG). It has been shown that the uptake of FDG as detected by PET scanning correlates with inflammation in animal models as well as in human disease processes such as sarcoidosis, tuberculosis and abscess formation. In addition, it has been shown that the inflammation associated with allergen challenge in patients with atopic asthma can be visualized using ...

Gender

ALL

Eligibility criteria

  • Subjects must be between 18 and 55 years of age.
  • Negative pregnancy test within two days of the scan and willingness to adhere to reliable birth control until the completion of the protocol.
  • Subjects must be able to give informed consent.
  • Subjects in the negative control group must have no history of asthma or other lung disease.
  • Control subjects must have negative prick skin tests to the allergens used.
  • Asthmatic subjects must have asthma as defined in this study.
  • Asthmatic subjects must have positive prick skin tests to one or more allergens used.
  • Subjects must have access to a primary medical care provider outside of the NIH.
  • Subjects must weigh less than 136 kg.
  • No breast feeding.
  • No smoking in the last 3 years, or greater than 6 months of smoking in the past ten years.
  • No antihistamines one week prior to the skin test on the first visit.
  • No history of coronary artery disease.
  • No evidence of lung disease other than asthma; no evidence of autoimmune or inflammatory disease which could affect lung function such as lupus erythematosus (except for the control subjects with Wegener's granulomatosis).
  • No evidence of either acute (e.g., bacterial or viral pneumonia) or chronic (e.g., bronchiectasis) lung infection.
  • No diabetes, or history of glucose intolerance (e.g., gestational diabetes).
  • No allergy to methacholine.
  • No beta-adrenergic blocking medication.
  • Control subjects must not have a history of asthma, atopic rhinitis or atopic dermatitis.
  • Control subjects must not have any response to inhaled methacholine with a fall in FEV1 in excess of 20% to less than or equal to 25 mg/ml.
  • Asthmatic subjects must not have chronic bronchitis or a diagnosis of chronic obstructive lung disease (COPD).

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials